Doctor profile · Federal record
Dr. Amanda Titus, MD
Rheumatology Physician (CMS: Rheumatology) · Oklahoma City, OK
- NPI 1750675971
- Accepts Medicare
- 15 yrs in practice
- Female
- Group practice
- No sanctions
Practice & contact
- Primary practice
-
4140 W Memorial RD, Suite 518
Oklahoma City, OK 731208366
(405) 752-3720
fax (405) 752-3721
Credentials & registration
- NPI registered
- June 2011 — 15 yrs on file
- Profile last updated
- October 18, 2016
- Year of graduation
- 2011 — 15 yrs since
- Specialty taxonomy
- 207RR0500X — NUCC code
- State license (1)
- Oklahoma #28509
Federal sanctions & exclusions
No sanctions, exclusions or revocations on file
Checked against OIG LEIE on NPI 1750675971. Last verified May 11, 2026.Medicare procedures · 2023
Top services delivered
Total services
11,780
Distinct HCPCS
10
Medicare allowed
$261,581
| HCPCS | Description | Services | Patients | Avg allowed | |
|---|---|---|---|---|---|
J1602 |
Injection, golimumab, 1 mg, for intravenous use | 8,250 | 12 | $13 | |
J0897 |
Injection, denosumab, 1 mg | 2,460 | 25 | $23 | |
99214 |
Established patient office or other outpatient visit, 30-39 minutes | 486 | 230 | $119 | |
96372 |
Injection of drug or substance under skin or into muscle | 166 | 34 | $13 | |
96413 |
Administration of chemotherapy into vein, 1 hour or less | 117 | 17 | $114 | |
99204 |
New patient office or other outpatient visit, 45-59 minutes | 105 | 105 | $153 | |
96365 |
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 100 | 17 | $58 | |
99213 |
Established patient office or other outpatient visit, 20-29 minutes | 45 | 38 | $84 | |
73120 |
X-ray of hand, 2 views | 36 | 18 | $29 | |
72100 |
X-ray of lower and sacral spine, 2-3 views | 15 | 15 | $37 |
In context: peer comparison
Among 8 peers in Oklahoma City Rheumatology Physician, average services per provider: 517. This provider delivers 23× the peer median.Open Payments
Industry payments received
All-time total
$2,351
Transactions
123
Manufacturers
15
| Payer (manufacturer) | Industry | Txns | Amount |
|---|---|---|---|
| Abbvie INC. | 40 | $661.86 | |
| Amgen INC. | 24 | $356.87 | |
| AstraZeneca Pharmaceuticals Lp | 13 | $299.14 | |
| Janssen Biotech, INC. | 11 | $269.33 | |
| Ucb, INC. | 14 | $193.05 | |
| Ani Pharmaceuticals, INC. | 2 | $103.44 | |
| Novartis Pharmaceuticals Corporation | 4 | $86.00 | |
| Genzyme Corporation | 1 | $78.94 | |
| Lilly USA, LLC | 3 | $75.34 | |
| Sandoz INC. | 3 | $64.95 | |
| GlaxoSmithKline, LLC. | 3 | $46.10 | |
| Fresenius Kabi USA, LLC | 2 | $45.24 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | 1 | $39.59 | |
| Aurinia Pharma U.S., INC. | 1 | $15.97 | |
| Alexion Pharmaceuticals, INC. | 1 | $15.26 |
By nature of payment
Medicare Part D · 2023
Top prescriptions
Total claims
1,052
Patients
319
Total drug cost
$827,314
| Drug | Type | Claims | Patients | Total cost |
|---|---|---|---|---|
| Prednisone | Generic | 218 | 78 | $1,817 |
| Hydroxychloroquine Sulfate | Generic | 207 | 67 | $14,035 |
| Methotrexate (Methotrexate Sodium) | Brand | 179 | 66 | $5,784 |
| Folic Acid | Generic | 63 | 23 | $326 |
| Sulfasalazine Dr (Sulfasalazine) | Brand | 58 | 21 | $2,728 |
| Gabapentin | Generic | 55 | 21 | $1,046 |
| Humira(Cf) Pen (Adalimumab) | Brand | 40 | 0 | $272,765 |
| Leflunomide | Generic | 40 | 14 | $2,125 |
| Alendronate Sodium | Generic | 36 | 13 | $440 |
| Meloxicam | Generic | 35 | 16 | $198 |
Frequently asked questions
What is Dr. Amanda Titus's medical specialty?
Dr. Amanda Titus practices Rheumatology Physician in Oklahoma City, OK.
Where does Dr. Amanda Titus practice?
Dr. Amanda Titus practices at 4140 W Memorial RD, Oklahoma City, OK 731208366. Office phone: 4057523720.
What is Dr. Amanda Titus's NPI?
Dr. Amanda Titus's National Provider Identifier (NPI) is 1750675971, issued by NPPES.
Does Dr. Amanda Titus accept Medicare assignment?
Yes. Dr. Amanda Titus accepts Medicare assignment, meaning Medicare-allowed amounts are accepted as full payment for covered services.
What procedures does Dr. Amanda Titus commonly perform?
Top Medicare-reported procedures in 2023: Injection, golimumab, 1 mg, for intravenous use (HCPCS J1602); Injection, denosumab, 1 mg (HCPCS J0897); Established patient office or other outpatient visit (HCPCS 99214). Source: CMS Medicare Physician & Other Practitioners file.